2RH Stock Chart & Stats
€8.00
€0.00(0.00%)
At close: 4:00 PM EST
€8.00
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€7.33 - €8.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€3.76M
Enterprise Value-€433.86K
Total Cash (Recent Filing)€2.87M
Total Debt (Recent Filing)€214.00K
Price to Earnings (P/E)―
Beta-9.11
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.00
Shares Outstanding6,080,920
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.76
Price to Sales (P/S)11.38
P/FCF Ratio-0.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€43.92M
Bulls Say, Bears Say
Bulls Say
Balance Sheet RepairA materially lower debt load and return to positive equity in 2025 materially reduce near-term solvency risk and refinancing pressure. This improved capital structure increases optionality to execute M&A, partnerships or pipeline programs without immediate distress financing.
Regulatory Designation For OpaganibRare pediatric disease designation (and orphan status) provides potential regulatory and commercial advantages, including eligibility for Priority Review Vouchers and exclusivity benefits. This strengthens opaganib's long-term development value and partnership/commercial prospects in pediatric oncology.
Advanced Pipeline Candidate (RHB-204)Next‑gen RHB-204 showing comparable MAP efficacy at lower doses supports a differentiated oral Crohn’s therapy strategy. If clinical benefit in MAP-positive patients holds, the asset could restore durable product revenues in a large, growing Crohn’s market and attract non-dilutive partners.
Bears Say
Severe Revenue DeclineA collapse in top-line scale undermines operating leverage and commercial viability: such a dramatic decline reduces bargaining power with payers/distributors, limits reinvestment capacity, and makes consistent margin recovery and sustained commercial growth a multi-period challenge.
Persistent Cash BurnDeep, recurring negative operating cash flow signals an ongoing funding gap. Persistently negative free cash generation forces management to prioritize financing over long-term R&D/commercial investments, increasing execution risk for late‑stage programs and potential dilution if asset sales or rights offerings are needed.
Reliance On Dilutive FinancingFrequent equity/ATM placements and warrant financings indicate ongoing dependency on capital markets to fund operations. This dilutive funding model can erode shareholder value, constrain long-term investor support, and reflect limited internal cash generation to sustain pipeline and commercialization plans.
RedHill Biopharma News
2RH FAQ
What was RedHill Biopharma’s price range in the past 12 months?
RedHill Biopharma lowest stock price was €7.33 and its highest was €8.00 in the past 12 months.
What is RedHill Biopharma’s market cap?
RedHill Biopharma’s market cap is €3.76M.
When is RedHill Biopharma’s upcoming earnings report date?
RedHill Biopharma’s upcoming earnings report date is Aug 20, 2026 which is in 30 days.
How were RedHill Biopharma’s earnings last quarter?
Currently, no data Available
Is RedHill Biopharma overvalued?
According to Wall Street analysts RedHill Biopharma’s price is currently Overvalued.
Does RedHill Biopharma pay dividends?
RedHill Biopharma does not currently pay dividends.
What is RedHill Biopharma’s EPS estimate?
RedHill Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RedHill Biopharma have?
RedHill Biopharma has 6,080,920 shares outstanding.
What happened to RedHill Biopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of RedHill Biopharma?
Currently, no hedge funds are holding shares in DE:2RH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RedHill Biopharma
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
Technical Analysis
China Pharma Holdings
―
Sonoma Pharmaceuticals
―
PainReform
―
Universe Pharmaceuticals
―
Shuttle Pharmaceuticals Holdings, Inc.
―